RECENT Healthcare RESEARCH
In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.
In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.
Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a “hold,” and one recommends a “sell.”
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
Antares Pharma’s (ATRS) products include Vibex, a pressure-assisted autoinjector. The global injectable drug delivery market is expected to grow to $624.5 billion by 2021.
So far this week (starting November 13, 2017), natural gas (UNG) (BOIL) prices are leading a decline in energy commodities.
In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.
Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.
In 3Q17, Align Technology reported total revenues close to $385.3 million, which represents YoY growth of ~38.3% and QoQ growth of ~8.1%.
Zimmer Biomet Holdings (ZBH) reported sales of approximately $1.8 billion in 3Q17, which ended on September 30, 2017. The company released its 3Q17 results on November 1, 2017.
The Rhode Island–based CVS Health (CVS) reported its results for 3Q17 on Monday, November 6. The results relate to the three-month period that ended on September 30, 2017.
In 3Q17, Celgene (CELG) generated revenues of $3.3 billion, which reflected ~10.0% growth year-over-year. Celgene reported an operating margin of ~59.5%.
Pfizer (PFE) released its 3Q17 earnings on October 31, 2017, reporting another strong quarter in its Innovative Health business, with a 1% growth in revenues.
In 3Q17, Roche Holding (RHHBY) generated revenues of 13.1 billion Swiss francs, which was a ~5% rise YoY. Revenues for its Pharmaceuticals segment rose ~4%, and its Diagnostics segment rose ~6%.
In this series, we’ll look at some key growth drivers for Sarepta Therapeutics.
Bristol-Myers Squibb’s (BMY) product portfolio includes drugs from various therapeutic areas including Cardiovascular, Virology, Immunoscience, Neuroscience, and Oncology. The chart below shows the revenues of Bristol-Myers Squibb since 4Q15. Because…
Analysts estimate that Sanofi’s gross profit margin will fall 1.2% to 70.6% during 3Q17 as compared to its gross profit margin of 71.8% during 3Q16.
In 3Q17, Amgen (AMGN) generated revenues of around $5.8 billion, a ~1% decline on a year-over-year (or YoY) basis and a ~1% decline on a quarter-over-quarter basis.
On September 19, 2016, Sarepta Therapeutics’ (SRPT) Exondys 51 got approval from the FDA as a therapy for Duchenne muscular dystrophy in patients with a mutation in the dystrophin gene that is amenable to exon 51 skipping.